NORTHERN-TRUST
15.11.2021 09:02:05 CET | Business Wire | Press release
Northern Trust Asset Management (NTAM), one of the world’s leading investment managers, has appointed Alexandra Kovalenko as head of its Swedish branch, with responsibility for leading sales across the Nordic region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115005015/en/
Kovalenko’s appointment closely follows Northern Trust Asset Management’s continued growth in the Nordic region which recently saw the expansion of its Exchange Traded Funds (ETF) footprint, with the launch of four sustainability with quality low-volatility and income strategies registered in the UK, Ireland, Germany, Sweden, and the Netherlands.
“At Northern Trust Asset Management, we believe investors should be compensated for the risks they take – in all market environments and any investment strategy, said Marie Dzanis, head of NTAM for Europe, Middle East and Africa (EMEA) . “We’re seeing continued demand from investors across the Nordic region for sustainable investing solutions, particularly within our Environmental, Social and Governance (ESG) quantitative active strategies and ETF funds. Through Alexandra’s leadership, expertise and local experience, we will be well placed to support our Nordic clients in achieving their investment goals.”
Kovalenko joined Northern Trust Asset Management in 2019, having previously held sales roles in Northern Trust’s Corporate & Institutional Services (C&IS) sales team which she joined in 2017. Prior to joining Northern Trust, she worked as an Equity Sales Trader with Goldman Sachs in London across multiple execution desks. Kovalenko holds a bachelor’s degree in Economics from UCL – University College London, UK.
Northern Trust Asset Management first established a presence in Sweden in 2009, following increased demand from Nordic based clients for its range of investment management solutions. It has established relationships in the region for more than 25 years and continues to expand its capabilities and local footprint. Northern Trust Asset Management is the 4th largest manager of Nordic pension assets in the Nordic region and the 4th largest manager of global equities as well as the 8th largest manager of Nordic institutional assets (according to the IPE Survey of Nordic Institutional Assets, December 2020).
About Northern Trust
Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 22 U.S. states and Washington, D.C., and across 23 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of September 30, 2021, Northern Trust had assets under custody/administration of US$15.8 trillion, and assets under management of US$1.5 trillion. For more than 130 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Please visit our website or follow us on Twitter .
Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Please read our global and regulatory information .
About Northern Trust Asset Management
Northern Trust Asset Management is a global investment manager that helps investors navigate changing market environments, so they can confidently realize their long-term objectives. Entrusted with US$1.2 trillion of investor assets as of September 30, 2021, we understand that investing ultimately serves a greater purpose and believe investors should be compensated for the risks they take — in all market environments and any investment strategy. That’s why we combine robust capital markets research, expert portfolio construction and comprehensive risk management to craft innovative and efficient solutions that deliver targeted investment outcomes. As engaged contributors to our communities, we consider it a great privilege to serve our investors and our communities with integrity, respect, and transparency.
Northern Trust Asset Management is composed of Northern Trust Investments, Inc., Northern Trust Global Investments Limited, Northern Trust Fund Managers (Ireland) Limited, Northern Trust Global Investments Japan, K.K., NT Global Advisors, Inc., 50 South Capital Advisors, LLC, Belvedere Advisors LLC and investment personnel of The Northern Trust Company of Hong Kong Limited and The Northern Trust Company.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
